1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Botulism - Pipeline Review, H1 2016

Botulism - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 49 pages

Botulism - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Botulism - Pipeline Review, H1 2016’, provides an overview of the Botulism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Botulism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Botulism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Botulism
- The report reviews pipeline therapeutics for Botulism by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Botulism therapeutics and enlists all their major and minor projects
- The report assesses Botulism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Botulism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Botulism
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Botulism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Botulism - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Botulism Overview 7
Therapeutics Development 8
Pipeline Products for Botulism - Overview 8
Pipeline Products for Botulism - Comparative Analysis 9
Botulism - Therapeutics under Development by Companies 10
Botulism - Therapeutics under Investigation by Universities/Institutes 11
Botulism - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Botulism - Products under Development by Companies 14
Botulism - Products under Investigation by Universities/Institutes 15
Botulism - Companies Involved in Therapeutics Development 16
Hawaii Biotech, Inc. 16
Medytox Solutions, Inc. 17
Microbiotix, Inc. 18
Molecular Targeting Technologies, Inc. 19
XOMA Corporation 20
Botulism - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
BoNT/A HcR4 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
botulinum vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
botulism [serotypes A, B, C, D, E] vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
botulism [serotypes A, B] vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Monoclonal Antibody to Inhibit Botulinum Toxin for Botulism - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
OSX-400 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
OSX-400 Backups - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Polyclonal Antibody for Botulism - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Recombinant Peptides to Inhibit Botulinum Toxin for Botulism - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Small Molecules for Botulism - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Small Molecules to Inhibit BoNT/A LC for Botulism - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Small Molecules to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
XOMA-3AB - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Botulism - Recent Pipeline Updates 44
Botulism - Dormant Projects 45
Botulism - Discontinued Products 46
Botulism - Product Development Milestones 47
Featured News and Press Releases 47
May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables
Number of Products under Development for Botulism, H1 2016 8
Number of Products under Development for Botulism - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Botulism - Pipeline by Hawaii Biotech, Inc., H1 2016 16
Botulism - Pipeline by Medytox Solutions, Inc., H1 2016 17
Botulism - Pipeline by Microbiotix, Inc., H1 2016 18
Botulism - Pipeline by Molecular Targeting Technologies, Inc., H1 2016 19
Botulism - Pipeline by XOMA Corporation, H1 2016 20
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Stage and Target, H1 2016 23
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 29
Botulism Therapeutics - Recent Pipeline Updates, H1 2016 44
Botulism - Dormant Projects, H1 2016 45
Botulism - Discontinued Products, H1 2016 46

List of Figures
Number of Products under Development for Botulism, H1 2016 8
Number of Products under Development for Botulism - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Targets, H1 2016 22
Number of Products by Stage and Targets, H1 2016 22
Number of Products by Mechanism of Actions, H1 2016 24
Number of Products by Stage and Mechanism of Actions, H1 2016 24
Number of Products by Routes of Administration, H1 2016 26
Number of Products by Stage and Routes of Administration, H1 2016 26
Number of Products by Molecule Types, H1 2016 28
Number of Products by Stage and Molecule Types, H1 2016 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.